Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2025 and 2026.
-
Busy address KBO
18 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2026
AVALO THERAPEUTICS EUROPE from Brussel, company number BE0716860484, closed financial year 2026 with a result of € -4,700 after tax. For that financial year AVALO THERAPEUTICS EUROPE recorded a gross margin of € -4,700 and equity of € 16,916. Compared with financial year 2025, the result moved from € -8,519 to € -4,700. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
€ 16,916
▼ 22% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -4,700
▲ 45 % less loss than in 2025
Profit after tax over the fiscal year.
€ 95,498
▲ 7% vs 2025
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -13,219.
People and assets in 2026
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2026
None
No bank loans on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | € -7,901 | € -7,978 | € -7,976 | € -4,700 | ▲ € 3,276 |
| Profit after taxes | € -8,405 | € -8,489 | € -8,519 | € -4,700 | ▲ € 3,819 |
| Equity | € 13,625 | € 5,135 | € 21,616 | € 16,916 | ▼ 22% |
| Total debts | € 47,843 | € 57,945 | € 68,261 | € 78,960 | ▲ 16% |
| Cash | € 61,113 | € 62,730 | € 89,498 | € 95,498 | ▲ 7% |
| Retained profit | € -39,925 | € -48,415 | € -8,519 | € -13,219 | ▼ € 4,700 |
| Balance sheet total | € 61,468 | € 63,080 | € 89,877 | € 95,876 | ▲ 7% |
Key figures of AVALO THERAPEUTICS EUROPE, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 28 December 2027.
What happened to AVALO THERAPEUTICS EUROPE?
What happened at AVALO THERAPEUTICS EUROPE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: loss of € 4,700. Source: NBB ↗
- Ann Dhoore became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 8,405 loss in 2023 to € 4,700 loss in 2026.
A new publication or filing at AVALO THERAPEUTICS EUROPE? We notify you, reason included.
Follow AVALO THERAPEUTICS EUROPEDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind AVALO THERAPEUTICS EUROPE is Ann Dhoore. Ann Dhoore is also behind maatWERKbedrijf BWB.
Directors
According to the 2026 annual accounts
since 2024
Establishments
Establishment units
Physical locations of this company
Barricadenplein 13
1000 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 18 companies are registered at this address.
All companies at this address →Société Coopérative pour le Développement Industriel en Afrique
Société des Habitations à Bon Marché
Domein van Vorselaar
€ 182,308 gross margin · 2025
DE BEUKEN
€ -14,127 gross margin · 2025
MERISANT EUROPE
€ 66,970 gross margin · 2025
+13 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0716.860.484
- VAT number
- BE 0716.860.484
- Registered office
- Barricadenplein 13, 1000 Brussel
- Names & denominations
- AVALO THERAPEUTICS EUROPE
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 December 2018
- Peppol
- Not registered